BR-61501

N/A

Report date: 2023/01/07 18:44:09
NME

Base Information

Drug NameBR-61501
Drug Alias NameBR-61501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Wangao Pharmaceutical Co LtdNingbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co LtdBrightgene Bio-Medical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBrightgene Bio-Medical Technology Co LtdJiangsu Wangao Pharmaceutical Co LtdNingbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A